MGO is a reactive byproduct of glucose metabolism. This discovery opens the door to earlier diagnosis and potential new treatments, offering hope for safer pregnancies.
In preeclampsia, the placenta does not develop properly, leading to poor blood flow and reduced oxygen supply. Dr. Vangrieken found that this lack of oxygen boosts glucose metabolism, which in turn increases MGO production.
High levels of MGO lead to the formation of harmful molecules known as advanced glycation end-products, or AGEs. These AGEs accumulate in the placenta and are released into the maternal circulation, where they disrupt blood vessel function, contributing to severe vascular complications.
A key aspect of this research is the use of state-of-the-art mass spectrometry technology to detect and quantify a comprehensive panel of compounds, including MGO and AGEs, with high precision. This advanced analysis not only sheds light on the biochemical changes in preeclampsia but also has broader applications, including screening for similar vascular issues in diseases such as diabetes.
Dr. Vangrieken’s team also discovered that the enzyme GLO1, which helps detoxify MGO, is less active in preeclampsia. This diminished GLO1 function further exacerbates MGO accumulation, increasing vascular damage in the mother. These findings provide critical insights into the interplay between reduced oxygen supply, impaired detoxification pathways, and the resulting vascular dysfunction observed in preeclampsia.
Next, the team tested two potential treatments: quercetin, a plant-derived antioxidant, and MitoQ, a mitochondria-targeted compound. In lab experiments, quercetin lowered MGO levels in placental cells, while MitoQ protected maternal blood vessels from MGO-induced dysfunction and damage. These results suggest that targeting MGO could not only protect both mother and baby during pregnancy, but also reduce the risk of long-term vascular complications for mothers after childbirth.
A highlight of the study is the identification of early biomarkers. The researchers demonstrated that MGO-derived AGEs can be detected in maternal blood as early as 12 weeks into pregnancy, before any preeclampsia symptoms appear. This breakthrough could allow healthcare providers to identify high-risk pregnancies much earlier, enabling timely interventions and better management.
Dr. Vangrieken’s research provides a new understanding of the biochemical causes of preeclampsia and proposes innovative approaches for early diagnosis and treatment. By targeting maternal vascular health and utilizing state-of-the-art mass spectrometry, this work sets the stage for groundbreaking therapies and highlights potential applications in other vascular diseases such as diabetes.
